Crispr « Search Results « Science and Enterprise

Start-Up Adapts Crispr for Molecular Detection, Raises $40M

By Alan, on October 17th, 2023%

A new company is underway that says it adapts the gene editing technique Crispr to make detecting nucleic acid targets like DNA or RNA faster and simpler. . . . → Read More: Start-Up Adapts Crispr for Molecular Detection, Raises $40M

One-Time Crispr HIV Therapy Given Fast-Track Status

By Alan, on July 20th, 2023%

A treatment for HIV taken just once, using the genome-editing technology Crispr, is receiving fast-track designation from the U.S. Food and Drug Administration. . . . → Read More: One-Time Crispr HIV Therapy Given Fast-Track Status

Crispr Therapy Shown to Reduce Harmful Gut Microbes

By Alan, on May 31st, 2023%

A clinical trial shows an oral therapy with engineered viruses delivers precise gene-edited payloads to reduce E. coli communities in the gut with no serious adverse effects. . . . → Read More: Crispr Therapy Shown to Reduce Harmful Gut Microbes

Crispr Therapy Shown to Remove E. Coli in Gut

By Alan, on May 5th, 2023%

New research with lab animals shows gene-edited viruses can target and remove harmful E. coli bacteria from the gut, including strains usually resistant to antibiotics. . . . → Read More: Crispr Therapy Shown to Remove E. Coli in Gut

Patent Issued for Crispr-Edited Viruses in Microbiome

By Alan, on October 3rd, 2022%

A biotechnology company developing gene-edited therapies for bacterial infections in the gut received a U.S. patent for viruses engineered as treatments. . . . → Read More: Patent Issued for Crispr-Edited Viruses in Microbiome

Patent Issued for Anti-Bacterial Viruses with Crispr Payloads

By Alan, on August 2nd, 2022%

A biotechnology company received a patent for its engineered viruses to deliver gene-edited treatments to combat bacterial infections in the microbiome. . . . → Read More: Patent Issued for Anti-Bacterial Viruses with Crispr Payloads

Early Trial Data Show Crispr Cancer Therapy Response

By Alan, on May 13th, 2022%

Initial results from a clinical trial show non-Hodgkin lymphoma patients receiving low doses of gene-edited T-cells achieve a clinical response, but with some adverse effects. . . . → Read More: Early Trial Data Show Crispr Cancer Therapy Response

Trial Begins Testing Crispr Gut Microbiome Therapy

By Alan, on April 20th, 2022%

A clinical trial is underway assessing a genetically edited oral drug designed to remove E. coli in the gut, a danger for patients with blood-related cancers. . . . → Read More: Trial Begins Testing Crispr Gut Microbiome Therapy

Patent Board Rules for Broad Inst. in Crispr Case

By Alan, on March 1st, 2022%

A U.S. patent appeals board ruled that the Broad Institute at Harvard and MIT is the discoverer of Crispr gene editing techniques in animal cells. . . . → Read More: Patent Board Rules for Broad Inst. in Crispr Case

Clinical Trial Underway for One-Time Crispr HIV Treatment

By Alan, on January 27th, 2022%

A clinical trial is underway assessing a therapy for HIV infections that aims to eradicate the virus with one dose of the gene-editing technique Crispr. . . . → Read More: Clinical Trial Underway for One-Time Crispr HIV Treatment

Subscribe for email alerts

Donate to Science & Enterprise

S&E on Mastodon

S&E on LinkedIn

S&E on Flipboard

Like us on Facebook

Specials

Guest Posts

Please share Science & Enterprise